Exalenz Bioscience Ltd (EXEN) - Product Pipeline Analysis, 2017 Update

  • ID: 4267324
  • Company Profile
  • 39 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Kibion AB
  • MedMira Inc
  • Meridian Bioscience Inc
  • MORE
Summary:

Exalenz Bioscience Ltd (Exalenz) carries out the development and commercialization of advanced medical systems for a range of gastrointestinal (GI) tract and liver disorders. The company harnesses its BreathID technology platform for assessment and monitoring of functional diseases. Its flagship product, BreathID Hp is a urea breath test for diagnosing, monitoring and managing gastric Helicobacter pylori (H. pylori) infection in adults. The BreathID Hp is US Food and Drug Administration (FDA) approved and CE-approved in Europe. The company offers products for detection of gastric adenocarcinoma, peptic ulcer disease and mucosa associated lymphoid tissue lymphoma. It works in collaboration with various clinical and industrial partners in Europe, Asia, the US and Israel. Exalenz is headquartered in Modiin, Israel.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Exalenz Bioscience Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy::

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Kibion AB
  • MedMira Inc
  • Meridian Bioscience Inc
  • MORE
List of Tables
List of Figures
Exalenz Bioscience Ltd Company Overview
Exalenz Bioscience Ltd Company Snapshot
Exalenz Bioscience Ltd Pipeline Products and Ongoing Clinical Trials Overview
Exalenz Bioscience Ltd - Pipeline Analysis Overview
Business Description
Exalenz Bioscience Ltd - Key Facts
Exalenz Bioscience Ltd - Major Products and Services
Exalenz Bioscience Ltd Pipeline Products by Development Stage
Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
Exalenz Bioscience Ltd Pipeline Products Overview
BreathID Methacetin Breath Test - Acute Liver Failure
BreathID Methacetin Breath Test - Acute Liver Failure Product Overview
BreathID Methacetin Breath Test - Acute Liver Failure Clinical Trial
BreathID Methacetin Breath Test - NASH
BreathID Methacetin Breath Test - NASH Product Overview
BreathID Methacetin Breath Test - NASH Clinical Trial
BreathID Test - Chronic Liver Disease
BreathID Test - Chronic Liver Disease Product Overview
BreathID Test - Chronic Liver Disease Clinical Trial
BreathID Test - Hepatocellular Carcinoma
BreathID Test - Hepatocellular Carcinoma Product Overview
BreathID Test - Hepatocellular Carcinoma Clinical Trial
BreathID Test - Pancreatitis
BreathID Test - Pancreatitis Product Overview
BreathID Test - Portal Hypertension
BreathID Test - Portal Hypertension Product Overview
Methacetin Breath Test - Acute Liver Failure
Methacetin Breath Test - Acute Liver Failure Product Overview
Exalenz Bioscience Ltd - Key Competitors
Exalenz Bioscience Ltd - Key Employees
Exalenz Bioscience Ltd - Key Employee Biographies
Exalenz Bioscience Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Exalenz Bioscience Ltd, Recent Developments
Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017
Nov 01, 2016: Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States
Mar 14, 2016: Exalenz Biosciences Announces Collaboration with ALF Study Group to use BreathID to Monitor Patients with Acute Liver Failure
Aug 03, 2015: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID to Monitor Patients with Cirrhosis Associated with NASH
Jun 04, 2015: Exalenz Bioscience Launches Clinical Study for Breath-Based Detection of Primary Liver Cancer (HCC)
May 06, 2015: Exalenz Launches Clinical Study Of BreathID Test For Hepatocellular Carcinoma
Apr 13, 2015: Exalenz Bioscience Announces New Published Data Confirming the Clinical Utility of its BreathID Test for Detecting H. Pylori in an Emergency Department Setting
Oct 21, 2014: Exalenz Bioscience Launches Pivotal Study of World’s First Breath-Based Test to Diagnose Clinically Significant Portal Hypertension
Sep 22, 2014: Deloitte Names EXALENZ as One of Israel's Companies-to-Watch in the 2014 Deloitte Technology Fast 50 Awards
Aug 21, 2013: Exalenz Granted US Patent for Liver Application of Company’s BreathID Platform Technology

Appendix
Methodology

About
Contact Us
Disclaimer

List of Tables:
Exalenz Bioscience Ltd Pipeline Products and Ongoing Clinical Trials Overview
Exalenz Bioscience Ltd Pipeline Products by Equipment Type
Exalenz Bioscience Ltd Pipeline Products by Indication
Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
Exalenz Bioscience Ltd, Key Facts
Exalenz Bioscience Ltd, Major Products and Services
Exalenz Bioscience Ltd Number of Pipeline Products by Development Stage
Exalenz Bioscience Ltd Pipeline Products Summary by Development Stage
Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
Exalenz Bioscience Ltd Ongoing Clinical Trials Summary
BreathID Methacetin Breath Test - Acute Liver Failure - Product Status
BreathID Methacetin Breath Test - Acute Liver Failure - Product Description
BreathID Methacetin Breath Test - Acute Liver Failure - 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure
BreathID Methacetin Breath Test - Acute Liver Failure - Assessment of the BreathID Methacetin Breath Test (MBT) Ability to Predict Patient Outcome in Acute Liver Failure (ALF)
BreathID Methacetin Breath Test - Acute Liver Failure - Clinical Study of the BreathID LF System to Train the Algorithm for the ¹³C-methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients with Compensated Liver Cirrhosis
BreathID Methacetin Breath Test - Acute Liver Failure - The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis
BreathID Methacetin Breath Test - NASH - Product Status
BreathID Methacetin Breath Test - NASH - Product Description
BreathID Methacetin Breath Test - NASH - Clinical Evaluation of BreathID Methacetin Breath Test (MBT) in Patients with Liver Cirrhosis Associated with Nonalcoholic Steatohepatitis (NASH) (ENCORE-PH)
BreathID Methacetin Breath Test - NASH - Clinical Study of Breath-based Diagnostic Test in Subjects with Nonalcoholic Steatohepatitis
BreathID Test - Chronic Liver Disease - Product Status
BreathID Test - Chronic Liver Disease - Product Description
BreathID Test - Chronic Liver Disease - 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure
BreathID Test - Hepatocellular Carcinoma - Product Status
BreathID Test - Hepatocellular Carcinoma - Product Description
BreathID Test - Hepatocellular Carcinoma - Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI in Patients with Chronic Liver Disease
BreathID Test - Pancreatitis - Product Status
BreathID Test - Pancreatitis - Product Description
BreathID Test - Portal Hypertension - Product Status
BreathID Test - Portal Hypertension - Product Description
Methacetin Breath Test - Acute Liver Failure - Product Status
Methacetin Breath Test - Acute Liver Failure - Product Description
Exalenz Bioscience Ltd, Key Employees
Exalenz Bioscience Ltd, Key Employee Biographies
Exalenz Bioscience Ltd, Subsidiaries
Glossary

List of Figures:
Exalenz Bioscience Ltd Pipeline Products by Equipment Type
Exalenz Bioscience Ltd Pipeline Products by Development Stage
Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Wagner Analysen Technik GmbH
  • Serim Research Corporation
  • Meridian Bioscience Inc
  • MedMira Inc
  • Kibion AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll